




January 2016 • Volume 9 • Number 1

LETTER FROM THE EDITOR

- 1 Catalyzing Cancer Prevention Research
CaPR: A New Year/New Opportunities
Scott M. Lippman

SPECIAL REPORT

- 2 Transforming Cancer Prevention through Precision Medicine and Immune-oncology
Thomas W. Kensler, Avrum Spira, Judy E. Garber, Eva Szabo, J. Jack Lee, Zigang Dong, Andrew J. Dannenberg, William N. Hait, Elizabeth Blackburn, Nancy E. Davidson, Margaret Foti, and Scott M. Lippman

EDITORIAL

- 11 Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals
Frank L. Meyskens Jr
See related article, p. 13

REVIEW

- 13 Risk Prediction Models for Colorectal Cancer: A Systematic Review
Juliet A. Usher-Smith, Fiona M. Walter, Jon D. Emery, Aung K. Win, and Simon J. Griffin
See related article, p. 11

RESEARCH ARTICLES

- 27 Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women
Mingyang Song, Raaj S. Mehta, Kana Wu, Charles S. Fuchs, Shuji Ogino, Edward L. Giovannucci, and Andrew T. Chan
- 35 Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of *Pten*-Knockout Mouse
Lei Wang, Xiaolan Guo, Ji Wang, Cheng Jiang, Maarten C. Bosland, Junxuan Lü, and Yibin Deng

- 43 Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non–Small Cell Lung Cancer and Its Potential as a Circulating Biomarker

Tzu-Fang Lou, Deepa Sethuraman, Patrick Dospoy, Pallevi Srivastva, Hyun Seok Kim, Joongsoo Kim, Xiaotu Ma, Pei-Hsuan Chen, Kenneth E. Huffman, Robin E. Frink, Jill E. Larsen, Cheryl Lewis, Sang-Won Um, Duk-Hwan Kim, Jung-Mo Ahn, Ralph J. DeBerardinis, Michael A. White, John D. Minna, and Hyuntae Yoo

- 53 Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer *In Vivo*

Venkateshwar Madka, Altaf Mohammed, Qian Li, Yuting Zhang, Laura Biddick, Jagan M.R. Patlolla, Stan Lightfoot, Rheel A. Towner, Xue-Ru Wu, Vernon E. Steele, Levy Kopelovich, and Chinthalapally V. Rao

- 63 Preclinical *In Vitro*, *In Vivo*, and Pharmacokinetic Evaluations of FLTL12 for the Prevention and Treatment of Head and Neck Cancers

Abu Syed Md Anisuzzaman, Abedul Haque, Mohammad Aminur Rahman, Dongsheng Wang, James R. Fuchs, Selwyn Hurwitz, Yuan Liu, Gabriel Sica, Fadlo R. Khuri, Zhuo (Georgia) Chen, Dong M. Shin, and A.R.M. Ruhul Amin

- 74 Anticancer and Cancer Prevention Effects of Piperine-Free *Piper nigrum* Extract on N-nitrosomethylurea-Induced Mammary Tumorigenesis in Rats

Somchai Sriwiriyan, Aman Tedasen, Narissara Lailerd, Pleumjit Boonyaphiphat, Anupong Nitruangjarat, Yan Deng, and Potchanapond Graidist

- 83 Uninterrupted Sedentary Behavior Downregulates *BRCA1* Gene Expression

Rachael Pettapiece-Phillips, Max Kotlyar, Rania Chehade, Leonardo Salmena, Steven A. Narod, Mohammad Akbari, Igor Jurisica, and Joanne Kotsopoulos

- 89 A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer

Matteo Lazzaroni, Aliana Guerrieri-Gonzaga, Sara Gandini, Harriet Johansson, Davide Serrano, Massimiliano Cazzaniga, Valentina Aristarco, Antonella Puccio, Serena Mora, Pietro Caldarella, Gianmatteo Pagani, Giancarlo Pruneri, Antonella Riva, Giovanna Petrangolini, Paolo Morazzoni, Andrea DeCensi, and Bernardo Bonanni

Table of Contents

96 Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma

Daniel T. Merrick, Dexiang Gao, York E. Miller, Robert L. Keith, Anna E. Baron, William Feser, Timothy C. Kennedy, Patrick J. Blatchford, Sarah Braudrick, Fred R. Hirsch, Lynn Heasley, Paul A. Bunn, Jr., and Wilbur A. Franklin

105 The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice

Martine Cao, Darlene B. Royce, Renee Risingsong, Charlotte R. Williams, Michael B. Sporn, and Karen T. Liby

LETTER TO THE EDITOR

115 Acrolein Levels in e-Cigarettes—Letter

CORRECTION

116 Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

 **AC icon indicates Author Choice**

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The molecular alterations associated with early pathological steps preceding the development of invasive carcinoma have not been well characterized. A Premalignant Cancer Genome Atlas (PCGA) is needed to both support the collection and molecular profiling (circus plot) of premalignant lesions (purple cells) to identify the sequence of initial driver events that cause normal cells (orange cells) to acquire cancer hallmarks that enable lesions (purple cells) to progress to fully invasive carcinoma, including the critical “additional genomic events” (e.g., checkpoint/tumor suppressor loss or other co-activating event) that transform premalignancy (purple cells in the fourth circle to the right) to cancer (far right). In addition to defining the sequence of site-specific genomic driving events, characterizing the premalignant inflammatory microenvironment, including the contribution of the stroma and immune cell (blue) regulation, will provide a better understanding of the selective forces that drive premalignant lesions to become invasive cancer. This figure appears in the Special Report by Kensler and colleagues (beginning on page 2), which sets out a brief agenda for the immediate future of cancer prevention, involving the inter-related fields of precision medicine and immunoprevention, driven by transformative approaches like PCGA, pivotal elements in a broader domain of personalized public health.

